

Shuhua Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4785827/publications.pdf>

Version: 2024-02-01

9
papers

114
citations

1478505

6
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

167
citing authors

#	ARTICLE	IF	CITATIONS
1	Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. <i>EBioMedicine</i> , 2021, 65, 103250.	6.1	11
2	Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. <i>Biomedicines</i> , 2021, 9, 1783.	3.2	1
3	Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. <i>Atherosclerosis</i> , 2020, 297, 111-119.	0.8	20
4	Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE ^{-/-} Mice. <i>Molecules</i> , 2019, 24, 4140.	3.8	7
5	Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE ^{-/-} mice by up-regulating heme oxygenase-1 via PI3K/Akt/Nrf2/ARE pathway. <i>FASEB Journal</i> , 2019, 33, 4836-4850.	0.5	34
6	Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo. <i>Biomedicine and Pharmacotherapy</i> , 2018, 98, 271-279.	5.6	4
7	Hirudin as a novel fusion tag for efficient production of lunasin in <i>Escherichia coli</i> . <i>Preparative Biochemistry and Biotechnology</i> , 2017, 47, 619-626.	1.9	6
8	A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2064.	4.1	9
9	Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo. <i>Oncotarget</i> , 2017, 8, 80826-80840.	1.8	22